-- 英国金融行为监管局（FCA）周三表示，万事达卡（Mastercard，股票代码：MA）、PayPal（股票代码：PYPL）和Visa（股票代码：V）正面临FCA根据1998年《竞争法》展开的调查，原因是涉嫌与PayPal数字钱包的资金筹集和使用相关的反竞争行为。 FCA补充说，目前尚未就违反竞争法做出任何结论或调查结果。 万事达卡发言人告诉，该公司已收到FCA的信息通知，要求其提供有关与PayPal合同关系的详细信息，并将与FCA进行全面、透明的合作。 Visa发言人在回复的电子邮件中也表示，FCA已告知该公司，已就PayPal数字钱包的某些合同条款展开调查。 PayPal尚未回复的置评请求。
Price: $497.14, Change: $+0.06, Percent Change: +0.01%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%